CSF levels of hypocretin-1 (Orexin-A) peak during early infancy in humans

Sleep

Volumn 35, Issue 2, 2012, Pages 187-191

  Aran, Adi ^a   Shors, Irina ^a   Lin, Ling ^b   Mignot, Emmanuel ^b   Schimmel, Michael S ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CSF; Fetus; Hypocretin; Infant; Orexin; Preterm; Sleep wake consolidation; Term

Indexed keywords

OREXIN A;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHILD; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; INFANCY; INFANT; MAJOR CLINICAL STUDY; MALE; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCHOOL CHILD; SLEEP PATTERN; THIRD TRIMESTER PREGNANCY;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; RADIOIMMUNOASSAY;

EID: 84856994898     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.1618     Document Type: Article

References (53)

1. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998;95:322-7. (Pubitemid 28103952)
2. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85. (Pubitemid 28101119)
3. Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ. Characterisation of the binding of [3H]-SB-674042, a novel non-peptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 2004;141:340-6. (Pubitemid 38250904)
4. Arii J, Kanbayashi T, Tanabe Y, et al. CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology 2004;63:2440-2. (Pubitemid 40024376)
5. Kanbayashi T, Yano T, Ishiguro H, et al. Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: infants to elderly persons. Sleep 2002;25:337-9. (Pubitemid 34496414)
6. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001;57:2253-8. (Pubitemid 34016460)
7. Henderson JM, France KG, Owens JL, Blampied NM. Sleeping through the night: the consolidation of self-regulated sleep across the first year of life. Pediatrics 2010;126:-1081-7.
8. John J, Wu MF, Maidment NT, et al. Developmental changes in CSF hypocretin-1 (orexin-A) levels in normal and genetically narcoleptic Doberman pinschers. J Physiol 2004;560(Pt 2):587-92. (Pubitemid 39440116)
9. Van Den Pol AN, Patrylo PR, Ghosh PK, Gao XB. Lateral hypothalamus: early developmental expression and response to hypocretin (orexin). J Comp Neurol 2001;433:349-63. (Pubitemid 32280656)
10. Yamamoto Y, Ueta Y, Hara Y, et al. Postnatal development of orexin/hypocretin in rats. Brain Res Mol Brain Res 2000;78:108-19. (Pubitemid 30417491)
11. Stoyanova, II, Rutten WL, le Feber J. Orexin-A and orexin-B during the postnatal development of the rat brain. Cell Mol Neurobiol 2009;30:81-9.
12. Dickinson H, Walker DW, Castillo-Melendez M. Onset of feeding at birth - perinatal development of the hypothalamic mechanisms that induce appetite and feeding in the newborn. Neurosci Lett 2008;436:1-6.
13. Faraco JH, Appelbaum L, Marin W, Gaus SE, Mourrain P, Mignot E. Regulation of hypocretin (orexin) expression in embryonic zebrafish. J Biol Chem 2006;281:29753-61. (Pubitemid 44536984)
14. Gautvik KM, de Lecea L, Gautvik VT, et al. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. Proc Natl Acad Sci U S A 1996;93:8733-8. (Pubitemid 26269629)
15. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015. (Pubitemid 28543775)
16. Beuckmann CT, Yanagisawa M. Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. J Mol Med 2002;80:329-42. (Pubitemid 34775371)
17. Nakabayashi M, Suzuki T, Takahashi K, et al. Orexin-A expression in human peripheral tissues. Mol Cell Endocrinol 2003;205:43-50. (Pubitemid 37297350)
18. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76. (Pubitemid 29380571)
19. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
20. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40. (Pubitemid 30072183)
21. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62.
22. Baskin MN. The prevalence of serious bacterial infections by age in febrile infants during the first 3 months of life. Pediatr Ann 1993;22:462-6.
23. Jaskiewicz JA, McCarthy CA, Richardson AC, et al. Febrile infants at low risk for serious bacterial infection - an appraisal of the Rochester criteria and implications for management. Febrile Infant Collaborative Study Group. Pediatrics 1994;94:390-6.
24. Wiswell TE, Baumgart S, Gannon CM, Spitzer AR. No lumbar puncture in the evaluation for early neonatal sepsis: will meningitis be missed? Pediatrics 1995;95:803-6.
25. Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-8. (Pubitemid 32848741)
26. Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 2003;54:96-104. (Pubitemid 36859768)
27. Bernard R, Lydic R, Baghdoyan HA. Hypocretin-1 causes G protein activation and increases ACh release in rat pons. Eur J Neurosci 2003;18:1775-85. (Pubitemid 37372362)
28. Acuna-Goycolea C, Li Y, Van Den Pol AN. Group III metabotropic glutamate receptors maintain tonic inhibition of excitatory synaptic input to hypocretin/orexin neurons. J Neurosci 2004;24:3013-22. (Pubitemid 38405748)
29. Muraki Y, Yamanaka A, Tsujino N, Kilduff TS, Goto K, Sakurai T. Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. J Neurosci 2004;24:7159-66. (Pubitemid 39096381)
30. Fu LY, Acuna-Goycolea C, van den Pol AN. Neuropeptide Y inhibits hypocretin/orexin neurons by multiple presynaptic and postsynaptic mechanisms: tonic depression of the hypothalamic arousal system. J Neurosci 2004;24:8741-51. (Pubitemid 39362969)
31. Soffin EM, Gill CH, Brough SJ, Jerman JC, Davies CH. Pharmacological characterisation of the orexin receptor subtype mediating postsynaptic excitation in the rat dorsal raphe nucleus. Neuropharmacology 2004;46:1168-76. (Pubitemid 38529940)
32. Tsujino N, Yamanaka A, Ichiki K, et al. Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. J Neurosci 2005;25:7459-69. (Pubitemid 41129819)
33. Li Y, van den Pol AN. Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons. J Neurosci 2005;25:173-83. (Pubitemid 40110778)
34. Yamanaka A, Muraki Y, Ichiki K, et al. Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner. J Neurophysiol 2006;96:284-98. (Pubitemid 44015360)
35. Frederick-Duus D, Guyton MF, Fadel J. Food-elicited increases in cortical acetylcholine release require orexin transmission. Neuroscience 2007;149:499-507. (Pubitemid 47633025)
36. Liu ZW, Gao XB. Adenosine inhibits activity of hypocretin/orexin neurons by the A1 receptor in the lateral hypothalamus: a possible sleep-promoting effect. J Neurophysiol 2007;97:837-48.
37. Ohno K, Hondo M, Sakurai T. Cholinergic regulation of orexin/hypocretin neurons through M(3) muscarinic receptor in mice. J Pharmacol Sci 2008;106:485-91. (Pubitemid 351468602)
38. Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol 2008;29:70-87.
39. Fadel J, Burk JA. Orexin/hypocretin modulation of the basal forebrain cholinergic system: Role in attention. Brain Res 2010;1314:112-23.
40. Han F. Respiratory regulation in narcolepsy. Sleep Breath 2011 [Epub ahead of print].
41. Zhang J, Li B, Yu L, et al. A role for orexin in central vestibular motor control. Neuron 2011;69:793-804.
42. Kuwaki T, Zhang W. Orexin neurons as arousal-associated modulators of central cardiorespiratory regulation. Respir Physiol Neurobiol 2010;174:43-54.
43. Bulbul M, Babygirija R, Ludwig K, Takahashi T. Central orexin-A increases gastric motility in rats. Peptides 2010;31:2118-22.
44. Moorman DE, Aston-Jones G. Orexin/hypocretin modulates response of ventral tegmental dopamine neurons to prefrontal activation: diurnal influences. J Neurosci 2010;30:15585-99.
45. Dergacheva O, Philbin K, Bateman R, Mendelowitz D. Hypocretin-1 (orexin A) prevents the effects of hypoxia/hypercapnia and enhances the GABAergic pathway from the lateral paragigantocellular nucleus to cardiac vagal neurons in the nucleus ambiguus. Neuroscience 2011;175:18-23.
46. Karnani MM, Venner A, Jensen LT, Fugger L, Burdakov D. Direct and indirect control of orexin/hypocretin neurons by glycine receptors. J Physiol 2011;589:639-51.
47. Kagerer SM, Eichholz C, Johren O. Orexins/hypocretins increase the promoter activity of selective steroidogenic enzymes. Peptides 2011 [Epub ahead of print].
48. So K, Adamson TM, Horne RS. The use of actigraphy for assessment of the development of sleep/wake patterns in infants during the first 12 months of life. J Sleep Res 2007;16:181-7. (Pubitemid 46850086)
49. Sadeh A, Mindell JA, Luedtke K, Wiegand B. Sleep and sleep ecology in the first 3 years: a web-based study. J Sleep Res 2009;18:60-73.
50. Sinton CM. Orexin/hypocretin plays a role in the response to physiological disequilibrium. Sleep Med Rev 2011 [Epub ahead of print].
51. Fox MW. Postnatal development of the EEG in the dog. 3. Summary and discussion of development of canine EEG. J Small Anim Pract 1967;8:71-112.
52. Harada S, Fujita-Hamabe W, Tokuyama S. Effect of orexin-A on post-ischemic glucose intolerance and neuronal damage. J Pharmacol Sci 2011;115:155-63.
53. Yuan LB, Dong HL, Zhang HP, et al. Neuroprotective effect of orexin-A is mediated by an increase of hypoxia-inducible factor-1 activity in rat. Anesthesiology 2011;114:340-54.